Edwards Lifesciences Reports Strong Q2 Sales Amid Anticipated Medicare Coverage Expansion
Edwards Lifesciences reported strong second-quarter sales, driven by robust demand in its transcatheter aortic valve replacement (TAVR) and newer mitral/tricuspid therapies. The company's TAVR business saw $1.26 billion in revenue with an 11.3% year-over-year increase, while total Q2 sales reached $1.74 billion—a 13.6% rise compared to the previous year. CEO Bernard Zovighian attributed this growth to increasing clinical evidence supporting earlier use of TAVR procedures. Edwards raised its full-year sales guidance to a range of 10-11%, citing strong performance and upcoming catalysts, including potential Medicare coverage expansion for asymptomatic patients expected in September. Analysts noted that the company's results should help alleviate concerns about procedure utilization declines seen earlier this earnings season among other healthcare providers. Looking ahead, key events include data from the PROGRESS trial on TAVR use in moderate aortic stenosis and the anticipated U.S. launch of new therapies like Pascal for tricuspid disease.